Lewis et al. [67] studied 1,715 hypertensive patients with nephropathy given irbesartan, amlodipine, or placebo. Mean duration of follow-up was 2.6 years. Treatment with irbesartan (300 mg ...

To investigate the synergism of low-doses of amlodipine and irbesartan on reduction of blood pressure variability (BPV), amelioration of baroreflex sensitivity (BRS) and organ protection in ...

As no studies have been published comparing the effects of irbesartan, amlodipine and standard blood pressure control in ESRD patients, we conservatively assumed that when a patient developed ESRD ...

We randomly assigned 1715 hypertensive patients with nephropathy due to type 2 diabetes to treatment with irbesartan (300 mg daily), amlodipine (10 mg daily), or placebo. The target blood pressure ...

In the randomized trial, investigators compared irbesartan (an angiotensin-receptor blocker), amlodipine (a calcium-channel blocker), and placebo. A manufacturer of irbesartan sponsored the trial.

took a single capsule containing four blood pressure-lowering drugs—irbesartan, amlodipine, hydrochlorothiazide, and atenolol—at quarter doses for 4 weeks. All of the 18 patients taking the ...

Irbesartan in combination with amlodipine plus hydrochlorothiazide is used to control high blood pressure, the release states. This recall is the latest in the past few months. Since July ...